Elevation Net Income From Continuing Ops from 2010 to 2024
| ELEV Stock | USD 0.62 0.01 1.59% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -56.8 M | Current Value -59.7 M | Quarterly Volatility 23.3 M |
Check Elevation Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Elevation Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 37 K, Interest Expense of 4.4 M or Selling General Administrative of 9.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.35. Elevation financial statements analysis is a perfect complement when working with Elevation Oncology Valuation or Volatility modules.
Elevation | Net Income From Continuing Ops |
Latest Elevation Oncology's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Elevation Oncology over the last few years. It is Elevation Oncology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Elevation Oncology's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Elevation Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (28,904,690) | |
| Coefficient Of Variation | (80.65) | |
| Mean Deviation | 17,071,545 | |
| Median | (17,265,000) | |
| Standard Deviation | 23,311,202 | |
| Sample Variance | 543.4T | |
| Range | 77.8M | |
| R-Value | (0.67) | |
| Mean Square Error | 319.9T | |
| R-Squared | 0.45 | |
| Significance | 0.01 | |
| Slope | (3,509,405) | |
| Total Sum of Squares | 7607.8T |
Elevation Net Income From Continuing Ops History
About Elevation Oncology Financial Statements
Elevation Oncology investors use historical fundamental indicators, such as Elevation Oncology's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Elevation Oncology. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -56.8 M | -59.7 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elevation Stock Analysis
When running Elevation Oncology's price analysis, check to measure Elevation Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elevation Oncology is operating at the current time. Most of Elevation Oncology's value examination focuses on studying past and present price action to predict the probability of Elevation Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elevation Oncology's price. Additionally, you may evaluate how the addition of Elevation Oncology to your portfolios can decrease your overall portfolio volatility.